69674-27-7

Basic information

• Product Name: 6-bromo-4-methylquinazoline
• Synonyms: 6-bromo-4-methylquinazoline
• CAS NO: 69674-27-7
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.0693
• Mol File: 69674-27-7.mol

Chemical Properties

• Boiling Point: 320.098 °C at 760 mmHg
• Flash Point: 147.39 °C
• Appearance: /
• Density: 1.566 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.663
• CAS DataBase Reference: 6-bromo-4-methylquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-4-methylquinazoline(69674-27-7)
• EPA Substance Registry System: 6-bromo-4-methylquinazoline(69674-27-7)

Safety Data

• Hazardous Substances Data: 69674-27-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-4-methylquinazoline is used as a pharmaceutical agent for its potential antiviral, anticancer, and anti-inflammatory properties. Its unique structure allows it to interact with specific biological targets, offering therapeutic benefits in treating various diseases and conditions.
Used in Medicinal Chemistry:
6-Bromo-4-methylquinazoline serves as a key intermediate in the synthesis of various quinazoline-based drugs. Its presence in the molecular structure can enhance the potency, selectivity, and pharmacokinetic properties of the resulting compounds, leading to the development of more effective medications.
Used in Drug Development:
As a quinazoline derivative, 6-bromo-4-methylquinazoline plays a crucial role in drug development. Its unique structural features and potential biological activities make it a valuable compound for designing and optimizing new drugs with improved therapeutic profiles.
Used as Fluorescent Probes:
6-Bromo-4-methylquinazoline and its derivatives have been investigated for their use as fluorescent probes. Their ability to emit light upon excitation can be utilized in various applications, such as imaging, sensing, and diagnostics, providing valuable insights into biological processes and molecular interactions.
Used in Organic Synthesis:
6-Bromo-4-methylquinazoline is also employed in the synthesis of various organic compounds. Its reactivity and functional groups make it a versatile building block for the preparation of complex organic molecules, contributing to the advancement of organic chemistry and the development of new materials and compounds.

InChI:InChI=1/C9H7BrN2/c1-6-8-4-7(10)2-3-9(8)12-5-11-6/h2-5H,1H3

Upstream product

• 551-93-9 2-aminoacetophenone 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 463-52-5 formamidine 
• 631-61-8 ammonium acetate 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 769916-07-6 C₉H₅BrN₂O₂ 
• 474710-78-6 methyl 6-bromoquinazolin-4-carboxylate 

Relevant articles and documents

SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF

The present application relates to a substituted aryl compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotope-labeled compound, a metabolite or a prodrug thereof, and a preparation method therefor and use thereof, also relates to a pharmaceutical composition containing the compound and a therapeutic use thereof. The compound or a pharmaceutical composition thereof can inhibit the activity of adenosine A2a receptor, and can be used for treating or preventing a disease related to adenosine A2a receptor, especially for treating a tumor.

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

Substituted pyrazine compound as well as preparation method and application thereof

The invention discloses a substituted pyrazine compound as an adenosine receptor antagonist, a preparation method and an intermediate thereof, a pharmaceutical composition containing the substituted pyrazine compound, and a therapeutic application of the

Aminopyrimidine compound and preparation method and application thereof

The invention relates to an aminopyrimidine compound and a preparation method and application thereof, in particular to an aminopyrimidine compound shown as a formula (I) or pharmaceutically acceptable salts thereof, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug, a pharmaceutical composition containing the compound, a preparation method of the compound and application of the compound to prevention or treatment of adenosine A2a receptor related diseases.

2-amino pyrimidine derivative, preparation method thereof and application thereof in medicine

The invention relates to 2-amino pyrimidine derivative, a preparation method thereof and an application thereof in medicine. In particular, the present invention relates to a 2-amino pyrimidine derivative shown in the general formula (I), a preparation method thereof, a pharmaceutical composition containing that derivative and use thereof as therapeutic agent, in particular as an A2a receptor and/or A2b receptor antagonist and in the preparation of a drug for the treatment of a condition or disorder improved by inhibition of the A2a receptor and/or A2b receptor, wherein the substituents of thegeneral formula (I) are the same as defined in the specification.

1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and use thereof as a therapeutic agent, in particular as an A2a receptor antagonist, and use thereof in the preparation of a medicament for treating a condition or disorder that is ameliorated by means of inhibition of the A2a receptor, each substituent in general formula (I) being same as defined in the description.